{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:17:18Z","timestamp":1781709438895,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study was financed by Sanofi Deutschland GmbH, Berlin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40273-018-0614-9","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T15:10:40Z","timestamp":1517411440000},"page":"477-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia"],"prefix":"10.1007","volume":"36","author":[{"given":"Axel C.","family":"M\u00fchlbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Werner","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Juhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"issue":"2","key":"614_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","volume":"15","author":"E Bruckert","year":"2014","unstructured":"Bruckert E, Saheb S, Bont\u00e9 JR, Coudray-Omn\u00e8s C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl. 2014;15(2):46\u201351.","journal-title":"Atheroscler Suppl."},{"key":"614_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/CEOR.S43087","volume":"5","author":"S Walzer","year":"2013","unstructured":"Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon Outcomes Res. 2013;5:189.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"614_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133\u201340.","journal-title":"J Clin Lipidol."},{"issue":"2","key":"614_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262\u20138.","journal-title":"Atherosclerosis."},{"issue":"2","key":"614_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.atherosclerosissup.2014.07.004","volume":"15","author":"E Bruckert","year":"2014","unstructured":"Bruckert E. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. Atheroscler Suppl. 2014;15(2):26\u201332.","journal-title":"Atheroscler Suppl."},{"issue":"2","key":"614_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2014.07.003","volume":"15","author":"RD Santos","year":"2014","unstructured":"Santos RD. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs? Atheroscler Suppl. 2014;15(2):19\u201325.","journal-title":"Atheroscler Suppl."},{"key":"614_CR7","first-page":"349","volume":"9","author":"U Julius","year":"2016","unstructured":"Julius U. Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein (a): current perspectives and patient selection. Med Dev (Auckl). 2016;9:349\u201360.","journal-title":"Med Dev (Auckl)."},{"key":"614_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TACG.S44315","volume":"8","author":"A Vogt","year":"2015","unstructured":"Vogt A. The genetics of familial hypercholesterolemia and emerging therapies. Appl Clin Genet. 2015;8:27\u201336.","journal-title":"Appl Clin Genet."},{"issue":"1","key":"614_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2012.10.021","volume":"14","author":"C Stefanutti","year":"2013","unstructured":"Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14(1):19\u201327.","journal-title":"Atheroscler Suppl."},{"issue":"48","key":"614_CR10","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, Cornier M-A, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37(48):3545\u20138.","journal-title":"Eur Heart J"},{"issue":"2","key":"614_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1086\/208753","volume":"6","author":"RW Olshavsky","year":"1979","unstructured":"Olshavsky RW, Granbois DH. Consumer decision making\u2014fact or fiction? J Consumer Res. 1979;6(2):93\u2013100.","journal-title":"J Consumer Res."},{"issue":"4","key":"614_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/1312067-200801040-00003","volume":"1","author":"FR Johnson","year":"2008","unstructured":"Johnson FR. Why not ask? Measuring patient preferences for healthcare decision making. Patient. 2008;1(4):245\u20138.","journal-title":"Patient."},{"issue":"2","key":"614_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jama.1996.03530260066035","volume":"275","author":"C Laine","year":"1996","unstructured":"Laine C, Davidoff F. Patient-centered medicine: a professional evolution. JAMA. 1996;275(2):152\u20136.","journal-title":"JAMA"},{"issue":"2","key":"614_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1037\/a0018963","volume":"117","author":"Y Trope","year":"2010","unstructured":"Trope Y, Liberman N. Construal-level theory of psychological distance. Psychol Rev. 2010;117(2):440.","journal-title":"Psychol Rev"},{"issue":"3","key":"614_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0277-9536(02)00056-4","volume":"56","author":"S Ford","year":"2003","unstructured":"Ford S, Schofield T, Hope T. What are the ingredients for a successful evidence-based patient choice consultation? A qualitative study. Soc Sci Med. 2003;56(3):589\u2013602.","journal-title":"Soc Sci Med."},{"issue":"510","key":"614_CR16","first-page":"6","volume":"55","author":"A Edwards","year":"2005","unstructured":"Edwards A, Elwyn G, Wood F, Atwell C, Prior L, Houston H. Shared decision making and risk communication in practice: a qualitative study of GPs\u2019 experiences. Br J Gen Pract. 2005;55(510):6.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"614_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1369-7625.2006.00401.x","volume":"9","author":"A Edwards","year":"2006","unstructured":"Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect. 2006;9(4):307\u201320.","journal-title":"Health Expect"},{"issue":"2","key":"614_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0277-9536(85)90079-6","volume":"21","author":"EJ Speedling","year":"1985","unstructured":"Speedling EJ, Rose DN. Building an effective doctor-patient relationship: from patient satisfaction to patient participation. Soc Sci Med. 1985;21(2):115\u201320.","journal-title":"Soc Sci Med"},{"issue":"3","key":"614_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1369-6513.2000.00093.x","volume":"3","author":"M Holmes-Rovner","year":"2000","unstructured":"Holmes-Rovner M, Valade D, Orlowski C, Draus C, Nabozny-Valerio B, Keiser S. Implementing shared decision-making in routine practice: barriers and opportunities. Health Expect. 2000;3(3):182\u201391.","journal-title":"Health Expect"},{"issue":"3","key":"614_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40258-016-0232-7","volume":"14","author":"A M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher A, Johnson FR. Choice experiments to quantify preferences for health and healthcare: state of the practice. Appl Health Econ Health Policy. 2016;14(3):253\u201366.","journal-title":"Appl Health Econ Health Policy."},{"issue":"3","key":"614_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40258-013-0023-3","volume":"11","author":"A M\u00fchlbacher","year":"2013","unstructured":"M\u00fchlbacher A, Juhnke C. Patient preferences versus physicians\u2019 judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy. 2013;11(3):163\u201380.","journal-title":"Appl Health Econ Health Policy."},{"issue":"1","key":"614_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/clc.4960220106","volume":"22","author":"HL Kennedy","year":"1999","unstructured":"Kennedy HL. The importance of randomized clinical trials and evidence-based medicine: a clinician\u2019s perspective. Clin Cardiol. 1999;22(1):6\u201312.","journal-title":"Clin Cardiol"},{"issue":"4","key":"614_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40271-017-0250-z","volume":"10","author":"FR Johnson","year":"2017","unstructured":"Johnson FR, Beusterien K, \u00d6zdemir S, Wilson L. Giving patients a meaningful voice in United States regulatory decision making: the role for health preference research. Patient. 2017;10(4):523\u20136. https:\/\/doi.org\/10.1007\/s40271-017-0250-z","journal-title":"Patient."},{"issue":"4","key":"614_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40271-017-0249-5","volume":"10","author":"AC M\u00fchlbacher","year":"2017","unstructured":"M\u00fchlbacher AC, Johnson FR. Giving patients a meaningful voice in European health technology assessments: the role of health preference research. Patient. 2017;10(4):527\u201330. https:\/\/doi.org\/10.1007\/s40271-017-0249-5","journal-title":"Patient."},{"key":"614_CR25","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlicheit im Gesundheitswesen (IQWiG). Wahlbasierte Conjoint-Analyse\u2014Pilotprojekt zur Identifikation, Gewichtung und Priorisierung multipler Attribute in der Indikation Hepatitis C; IQWiG-Berichte\u2014Nr. 227 [Pilot study: Conjoint Analysis in the indication \u201chepatitis C\u201d]. K\u00f6ln; 2014. https:\/\/www.iqwig.de\/en\/projects-results\/projects\/health-economic\/ga10-03-pilot-study-conjoint-analysis-in-the-indication-hepatitis-c.1411.html . Accessed 24 Jan 2018."},{"issue":"6","key":"614_CR26","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/hex.12201","volume":"18","author":"P Alonso-Coello","year":"2015","unstructured":"Alonso-Coello P, Montori VM, D\u00edaz MG, Devereaux PJ, Mas G, Diez AI, et al. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. Health Expect. 2015;18(6):2318\u201327.","journal-title":"Health Expect"},{"key":"614_CR27","doi-asserted-by":"crossref","unstructured":"Cutler D, Skinner J, Stern AD, Wennberg D. Physician beliefs and patient preferences: a new look at regional variation in health care spending. NBER Working Paper no. 19320. Cambridge: National Bureau of Economic Research; 2013.","DOI":"10.3386\/w19320"},{"key":"614_CR28","volume-title":"Getting started with conjoint analysis","author":"B Orme","year":"2010","unstructured":"Orme B. Getting started with conjoint analysis. Madison: Research Publishers LLC; 2010."},{"key":"614_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocm.2015.09.001","volume":"16","author":"J-C Yang","year":"2015","unstructured":"Yang J-C, Johnson FR, Kilambi V, Mohamed AF. Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach. J Choice Model. 2015;16:50\u20137.","journal-title":"J Choice Model."},{"issue":"5","key":"614_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW Bekker-Grob de","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384.","journal-title":"Patient."},{"issue":"2","key":"614_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1086\/259131","volume":"74","author":"KJ Lancaster","year":"1966","unstructured":"Lancaster KJ. A new approach to consumer theory. J Polit Econ. 1966;74(2):132\u201357.","journal-title":"J Polit Econ."},{"key":"614_CR32","first-page":"105","volume":"1974","author":"D McFadden","year":"1974","unstructured":"McFadden D. Conditional logit analysis of qualitative choice behavior. Zarembka. 1974;1974:105\u201342.","journal-title":"Zarembka."},{"key":"614_CR33","volume-title":"Discrete choice analysis: theory and application to travel demand","author":"ME Ben-Akiva","year":"1985","unstructured":"Ben-Akiva ME, Lerman SR. Discrete choice analysis: theory and application to travel demand. Cambridge: MIT; 1985."},{"key":"614_CR34","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610356","volume-title":"Applied choice analysis: a primer","author":"DA Hensher","year":"2005","unstructured":"Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005."},{"issue":"8","key":"614_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201378.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"614_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"J Bridges","year":"2009","unstructured":"Bridges J, Hauber A, Marshall D, Lloyd A, Prosser L, Regier D, et al. Checklist for conjoint analysis applications in health: report of the ISPOR Conjoint Analysis Good Research Practices Taskforce. Value Health. 2009;14(4):403\u201313.","journal-title":"Value Health."},{"issue":"4","key":"614_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-0032-1330500","volume":"18","author":"A M\u00fchlbacher","year":"2013","unstructured":"M\u00fchlbacher A, Bethge S, Tockhorn A. Pr\u00e4ferenzmessung im Gesundheitswesen: Grundlagen von Discrete-Choice-Experimenten. Gesundheits\u00f6konomie Qualit\u00e4tsmanagement. 2013;18(4):159\u201372.","journal-title":"Gesundheits\u00f6konomie Qualit\u00e4tsmanagement."},{"issue":"4","key":"614_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/1312067-200801040-00009","volume":"14","author":"JF Bridges","year":"2008","unstructured":"Bridges JF, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982\u20132007. Patient. 2008;14(4):273\u201382.","journal-title":"Patient."},{"key":"614_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831","volume-title":"Stated choice methods: analysis and application","author":"JJ Louviere","year":"2000","unstructured":"Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and application. Cambridge: Cambridge University Press; 2000."},{"key":"614_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5753-3","volume-title":"Using discrete choice experiments to value health and health care","author":"M Ryan","year":"2008","unstructured":"Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2008."},{"key":"614_CR41","doi-asserted-by":"crossref","unstructured":"M\u00fchlbacher AC, Kaczynski A, Dippel F-W, Bethge S. Patient priorities in adjunctive drug therapy of severe hypercholesterolemia in Germany: an analytic hierarchy process (AHP). Int J Technol Assess Health Care. 2017 (in press).","DOI":"10.1017\/S0266462318000247"},{"key":"614_CR42","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.03. Bethesda: National Institutes of Health, National Cancer Institute; 2010."},{"key":"614_CR43","unstructured":"ChoiceMetrics. NGene. http:\/\/www.choice-metrics.com . Accessed 24 Jan 2018."},{"key":"614_CR44","unstructured":"Rabe-Hesketh S, Skrondal A, Pickles A. GLLAMM manual. Division of Biostatistics Working Paper Series. Berkeley: University of California; 2004."},{"key":"614_CR45","unstructured":"IBM Corp. Released 2011. IBM SPSS Statistics for Windows, version 20.0. Armonk: IBM Corp.; 2011."},{"key":"614_CR46","unstructured":"StataCorp. Stata Statistical Software: release 13. College Station: StataCorp LP; 2013."},{"issue":"4","key":"614_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535\u201369.","journal-title":"Struct Equ Model"},{"issue":"4","key":"614_CR48","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.csda.2004.11.004","volume":"50","author":"C-C Yang","year":"2006","unstructured":"Yang C-C. Evaluating latent class analysis models in qualitative phenotype identification. Comput Stat Data Anal. 2006;50(4):1090\u2013104.","journal-title":"Comput Stat Data Anal"},{"key":"614_CR49","unstructured":"Hess S, Ben-Akiva M, Gopinath D, Walker J. Advantages of latent class choice models over continuous mixed logit models. In: Proceedings of the 12th international conference on travel behaviour research; 13\u201318 Dec 2009; Jaipur."},{"issue":"22","key":"614_CR50","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1080\/00036840801964633","volume":"41","author":"J Shen","year":"2009","unstructured":"Shen J. Latent class model or mixed logit model? A comparison by transport mode choice data. Appl Econ. 2009;41(22):2915\u201324.","journal-title":"Appl Econ"},{"key":"614_CR51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4337\/9781781003152","volume-title":"Handbook of choice modelling","author":"S Hess","year":"2014","unstructured":"Hess S. Chapter 14: Latent class structures: taste heterogeneity and beyond. In: Hess S, Daly A, editors. Handbook of choice modelling. Cheltenham: Edward Elgar Publishing Limited; 2014. p. 311\u201330."},{"key":"614_CR52","doi-asserted-by":"crossref","unstructured":"Roth EM, Bujas-Bobanovic M, Louie MJ, Cariou B. Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels. Clin Ther. 2015;37(9):1945\u201354 e6.","DOI":"10.1016\/j.clinthera.2015.07.008"},{"issue":"8","key":"614_CR53","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jval.2015.09.2937","volume":"18","author":"S Tatlock","year":"2015","unstructured":"Tatlock S, Grant L, Spertus JA, Khan I, Arbuckle R, Manvelian G, et al. Development and content validity testing of a patient-reported treatment acceptance measure for use in patients receiving treatment via subcutaneous injection. Value Health. 2015;18(8):1000\u20137.","journal-title":"Value Health."},{"issue":"7","key":"614_CR54","doi-asserted-by":"publisher","first-page":"A569","DOI":"10.1016\/j.jval.2014.08.1898","volume":"17","author":"S Tatlock","year":"2014","unstructured":"Tatlock S, Grant L, Arbuckle R, Khan I, Manvelian G, Sanchez R. Development and content validity testing of a treatment acceptance measure for use in hypercholesterolemia patients receiving treatment via subcutaneous injection. Value Health. 2014;17(7):A569.","journal-title":"Value Health."},{"issue":"31\u201332","key":"614_CR55","first-page":"523","volume":"111","author":"G Klose","year":"2014","unstructured":"Klose G, Laufs U, Marz W, Windler E. Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int. 2014;111(31\u201332):523\u20139.","journal-title":"Dtsch Arztebl Int."},{"issue":"16","key":"614_CR56","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"614_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2010.05.001","volume":"69","author":"P Blinman","year":"2010","unstructured":"Blinman P, Alam M, Duric V, McLachlan SA, Stockler MR. Patients\u2019 preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer. 2010;69(2):141\u20137.","journal-title":"Lung Cancer."},{"issue":"6","key":"614_CR58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10198-014-0622-4","volume":"16","author":"A M\u00fchlbacher","year":"2015","unstructured":"M\u00fchlbacher A, Bethge S. Patients\u2019 preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16(6):657\u201370.","journal-title":"Eur J Health Econ."},{"issue":"2","key":"614_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3727\/108354210X12724863327605","volume":"15","author":"PF Burke","year":"2010","unstructured":"Burke PF, Burton C, Huybers T, Islam T, Louviere JJ, Wise C. The scale-adusted latent class model: application to museum visitation. Tour Anal. 2010;15(2):147\u201365.","journal-title":"Tour Anal."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0614-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:52:12Z","timestamp":1693511532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0614-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"31 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Axel M\u00fchlbacher, Andrew Sadler, and Christin Juhnke declare that they have no further conflicts of interest. Franz-Werner Dippel was an employee of Sanofi Deutschland GmbH during the time of the conduction of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets on the respondents\u2019 choices generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}